Bionano Genomics, Inc. (NASDAQ:BNGO) Receives $7.50 Consensus Price Target from Brokerages

Shares of Bionano Genomics, Inc. (NASDAQ:BNGO) have been given an average recommendation of “Hold” by the four ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $7.50.

Several equities analysts have weighed in on BNGO shares. HC Wainwright restated a “buy” rating and set a $11.00 price target (up previously from $10.00) on shares of Bionano Genomics in a report on Monday, August 18th. Wall Street Zen upgraded Bionano Genomics from a “sell” rating to a “hold” rating in a research report on Monday, August 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bionano Genomics in a report on Saturday, September 27th.

Institutional Trading of Bionano Genomics

An institutional investor recently bought a new position in Bionano Genomics stock. Everstar Asset Management LLC purchased a new position in Bionano Genomics, Inc. (NASDAQ:BNGO) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 44,984 shares of the company’s stock, valued at approximately $126,000. Everstar Asset Management LLC owned approximately 1.45% of Bionano Genomics at the end of the most recent quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Stock Performance

Shares of NASDAQ BNGO opened at $1.92 on Friday. The company has a market cap of $7.95 million, a P/E ratio of -0.01 and a beta of 2.19. Bionano Genomics has a 52-week low of $1.50 and a 52-week high of $28.14. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.41 and a current ratio of 1.76. The firm’s fifty day moving average is $3.03 and its two-hundred day moving average is $3.40.

Bionano Genomics (NASDAQ:BNGO) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.69) by $0.70. Bionano Genomics had a negative return on equity of 129.41% and a negative net margin of 271.02%.The firm had revenue of $6.73 million during the quarter, compared to analyst estimates of $6.90 million. Bionano Genomics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.